|
|
|
|
International Clinical Trials |
| |
| International Clinical Trials (ICT) is a specialist journal designed to provide global coverage of
key topics pertinent to the clinical trials sector.
Published quarterly, the journal offers a platform of
communication and information-sharing for executive and strategic decision makers, seeking
out new trends and marketing opportunities, as well as putting a spotlight on the latest innovations coming to market. ICT is specifically designed to be of interest to those actively seeking to source services for improved efficiency in what is an increasingly competitive market.
Prompted by the synergies between trial operations and wider contract research and outsourcing
issues, ICT joined forces with sister title European Pharmaceutical Contractor (EPC) in late-2015,
in a move that brings added value to both brands. With EPC now an inserted edition within ICT,
industry practitioners across these complementary subject areas now
have unrivalled access
to a wealth of shared views and analyses.
Connect with us on Twitter: follow @IntClinTrials
Read
our publications on the go in the Samedan app for phones and tablets. You
can download issues for offline reading, and our archives go as far back
as 2008! Download for free on the App Store, GooglePlay, or Amazon.
  
|
|
|
|
|
|
 |
Industry Events |
 |
ESMO Targeted Anticancer Therapies Congress 2020
2-4 March 2020, Paris, France
A unique and international mix of experts, researchers and decision
makers both from academia and industry across the globe, will convene
in Paris for a three-day Congress aiming at exchanging knowledge,
experience and research innovations in cancer.
TAT
2020 will focus, among others, on novel strategies in immuno-oncology,
personalised medicine and molecular tumour boards, preclinical studies
to identify effective combination therapies, use of microbiome, tumour
agnostic trials, ADC technology, oncolytics, multispecific biological
constructs and targeting cytokines.
Participating in TAT 2020 will offer you the possibility to take part in
interdisciplinary discussions inspiring new ideas and new
collaborations.
More info >> |
|
 |
News and Press Releases |
 |
WuXi STA and Dizal Pharmaceutical Sign CMC Development and Manufacturing Agreement
STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec –
and Dizal Pharmaceutical, a biotechnology company, announce a strategic
partnership. Under the terms of the collaboration, WuXi STA will become
the preferred CDMO partner of Dizal Pharmaceutical for GMP production,
providing integrated CMC (Chemical, manufacturing and Control) process
research and manufacturing services from API to drug product.
More info >> |
|
 |
White Papers |
 |
|
Quality By Design
Biopharma Group
Quality by Design (QbD) is a systematic approach to development that begins with the defined objectives and emphasizes science and quality risk management in order to achieve those goals. QbD ensures that the quality of the product is built into production processes from the outset, rather than being tested after development has already commenced.
More info >> |
|
|
